Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers

Mathewos Tessema; Christin M. Yingling; Yushi Liu; Carmen S. Tellez; Leander Van Neste; Stephen S. Baylin; Steven A. Belinsky

doi:10.1093/carcin/bgt494

Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers

Mathewos Tessema, Christin M. Yingling, Yushi Liu, Carmen S. Tellez, Leander Van Neste, Stephen S. Baylin, Steven A. Belinsky^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Lung cancer in never smokers (NS) shows striking demographic, clinicopathological and molecular distinctions from the disease in smokers (S). Studies on selected genetic and epigenetic alterations in lung cancer identified that the frequency and profile of some abnormalities significantly differ by smoking status. This study compared the transcriptome of lung adenocarcinoma cell lines derived from S (n = 3) and NS (n = 3) each treated with vehicle (control), histone deacetylation inhibitor (trichostatin A) or DNA methylation inhibitor (5-aza-2'-deoxycytidine). Among 122 genes reexpressed following 5-aza-2'-deoxycytidine but not trichostatin A treatment in two or more cell lines (including 32 genes in S-only and 12 NS-only), methylation was validated for 80% (98/122 genes). After methylation analysis of 20 normal tissue samples and 14 additional non-small cell lung cancer cell lines (total 20), 39 genes frequently methylated in normal (>20%, 4/20) and 21 genes rarely methylated in non-small cell lung cancer (

Original language	English
Pages (from-to)	1248-1257
Journal	Carcinogenesis
Volume	35
Issue number	6
DOIs	https://doi.org/10.1093/carcin/bgt494
Publication status	Published - Jun 2014

Access to Document

10.1093/carcin/bgt494

Cite this

@article{0466d37763cf41b787dbe1b2c19dc255,

title = "Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers",

abstract = "Lung cancer in never smokers (NS) shows striking demographic, clinicopathological and molecular distinctions from the disease in smokers (S). Studies on selected genetic and epigenetic alterations in lung cancer identified that the frequency and profile of some abnormalities significantly differ by smoking status. This study compared the transcriptome of lung adenocarcinoma cell lines derived from S (n = 3) and NS (n = 3) each treated with vehicle (control), histone deacetylation inhibitor (trichostatin A) or DNA methylation inhibitor (5-aza-2'-deoxycytidine). Among 122 genes reexpressed following 5-aza-2'-deoxycytidine but not trichostatin A treatment in two or more cell lines (including 32 genes in S-only and 12 NS-only), methylation was validated for 80% (98/122 genes). After methylation analysis of 20 normal tissue samples and 14 additional non-small cell lung cancer cell lines (total 20), 39 genes frequently methylated in normal (>20%, 4/20) and 21 genes rarely methylated in non-small cell lung cancer (",

author = "Mathewos Tessema and Yingling, {Christin M.} and Yushi Liu and Tellez, {Carmen S.} and {Van Neste}, Leander and Baylin, {Stephen S.} and Belinsky, {Steven A.}",

year = "2014",

month = jun,

doi = "10.1093/carcin/bgt494",

language = "English",

volume = "35",

pages = "1248--1257",

journal = "Carcinogenesis",

issn = "0143-3334",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers

AU - Tessema, Mathewos

AU - Yingling, Christin M.

AU - Liu, Yushi

AU - Tellez, Carmen S.

AU - Van Neste, Leander

AU - Baylin, Stephen S.

AU - Belinsky, Steven A.

PY - 2014/6

Y1 - 2014/6

N2 - Lung cancer in never smokers (NS) shows striking demographic, clinicopathological and molecular distinctions from the disease in smokers (S). Studies on selected genetic and epigenetic alterations in lung cancer identified that the frequency and profile of some abnormalities significantly differ by smoking status. This study compared the transcriptome of lung adenocarcinoma cell lines derived from S (n = 3) and NS (n = 3) each treated with vehicle (control), histone deacetylation inhibitor (trichostatin A) or DNA methylation inhibitor (5-aza-2'-deoxycytidine). Among 122 genes reexpressed following 5-aza-2'-deoxycytidine but not trichostatin A treatment in two or more cell lines (including 32 genes in S-only and 12 NS-only), methylation was validated for 80% (98/122 genes). After methylation analysis of 20 normal tissue samples and 14 additional non-small cell lung cancer cell lines (total 20), 39 genes frequently methylated in normal (>20%, 4/20) and 21 genes rarely methylated in non-small cell lung cancer (

AB - Lung cancer in never smokers (NS) shows striking demographic, clinicopathological and molecular distinctions from the disease in smokers (S). Studies on selected genetic and epigenetic alterations in lung cancer identified that the frequency and profile of some abnormalities significantly differ by smoking status. This study compared the transcriptome of lung adenocarcinoma cell lines derived from S (n = 3) and NS (n = 3) each treated with vehicle (control), histone deacetylation inhibitor (trichostatin A) or DNA methylation inhibitor (5-aza-2'-deoxycytidine). Among 122 genes reexpressed following 5-aza-2'-deoxycytidine but not trichostatin A treatment in two or more cell lines (including 32 genes in S-only and 12 NS-only), methylation was validated for 80% (98/122 genes). After methylation analysis of 20 normal tissue samples and 14 additional non-small cell lung cancer cell lines (total 20), 39 genes frequently methylated in normal (>20%, 4/20) and 21 genes rarely methylated in non-small cell lung cancer (

U2 - 10.1093/carcin/bgt494

DO - 10.1093/carcin/bgt494

M3 - Article

C2 - 24398667

SN - 0143-3334

VL - 35

SP - 1248

EP - 1257

JO - Carcinogenesis

JF - Carcinogenesis

IS - 6

ER -